Search Results - (Author, Cooperation:D. Castellano)
-
1Latest Papers from Table of Contents or Articles in PressT. F. Mackay ; S. Richards ; E. A. Stone ; A. Barbadilla ; J. F. Ayroles ; D. Zhu ; S. Casillas ; Y. Han ; M. M. Magwire ; J. M. Cridland ; M. F. Richardson ; R. R. Anholt ; M. Barron ; C. Bess ; K. P. Blankenburg ; M. A. Carbone ; D. Castellano ; L. Chaboub ; L. Duncan ; Z. Harris ; M. Javaid ; J. C. Jayaseelan ; S. N. Jhangiani ; K. W. Jordan ; F. Lara ; F. Lawrence ; S. L. Lee ; P. Librado ; R. S. Linheiro ; R. F. Lyman ; A. J. Mackey ; M. Munidasa ; D. M. Muzny ; L. Nazareth ; I. Newsham ; L. Perales ; L. L. Pu ; C. Qu ; M. Ramia ; J. G. Reid ; S. M. Rollmann ; J. Rozas ; N. Saada ; L. Turlapati ; K. C. Worley ; Y. Q. Wu ; A. Yamamoto ; Y. Zhu ; C. M. Bergman ; K. R. Thornton ; D. Mittelman ; R. A. Gibbs
Nature Publishing Group (NPG)
Published 2012Staff ViewPublication Date: 2012-02-10Publisher: Nature Publishing Group (NPG)Print ISSN: 0028-0836Electronic ISSN: 1476-4687Topics: BiologyChemistry and PharmacologyMedicineNatural Sciences in GeneralPhysicsKeywords: Alleles ; Animals ; Centromere/genetics ; Chromosomes, Insect/genetics ; Drosophila melanogaster/*genetics ; *Genome-Wide Association Study ; *Genomics ; Genotype ; Phenotype ; Polymorphism, Single Nucleotide/genetics ; Quantitative Trait Loci/*genetics ; Selection, Genetic/genetics ; Starvation/genetics ; Telomere/genetics ; X Chromosome/geneticsPublished by: -
2Latest Papers from Table of Contents or Articles in PressLiu, X., Swen, J. J., Diekstra, M. H. M., Boven, E., Castellano, D., Gelderblom, H., Mathijssen, R. H. J., Vermeulen, S. H., Oosterwijk, E., Junker, K., Roessler, M., Alexiusdottir, K., Sverrisdottir, A., Radu, M. T., Ambert, V., Eisen, T., Warren, A., Rodriguez-Antona, C., Garcia-Donas, J., Böhringer, S., Koudijs, K. K. M., Kiemeney, L. A. L. M., Rini, B. I., Guchelaar, H.-J.
The American Association for Cancer Research (AACR)
Published 2018Staff ViewPublication Date: 2018-05-16Publisher: The American Association for Cancer Research (AACR)Print ISSN: 1078-0432Electronic ISSN: 1557-3265Topics: MedicinePublished by: -
3Articles: DFG German National LicensesPhase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neckHitt, R. ; Castellano, D. ; Hidalgo, M. ; García-Carbonero, R. ; Peña, M. ; Brandariz, A. ; Millán, J. M. ; Alvarez Vincent, J. J. ; Cortés-Funes, H.
Springer
Published 1998Staff ViewISSN: 1569-8041Keywords: advanced head and neck cancer ; cisplatin ; gemcitabine ; phase II trialSource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Abstract Background: To evaluate the toxicity profile and efficacy of cisplatin combined with gemcitabine in patients with irresectable locally recurrent or metastatic squamous cell carcinoma of the head and neck. Patients and methods: Gemcitabine was given at a dose of 800 mg/m2 on days 1, 8 and 15, plus cisplatin at a dose of 50 mg/m2 on days 1 and 8; every four weeks. Results: Twenty-four patients with a median age of 59 years (range 42–74) were included. All patients were evaluable for toxicity and 22 patients were assessable for response. Eleven cases had advanced recurrent locoregional disease while 13 patients had metastatic disease. One CR (4.7%) and four PR (18%) were observed, for an overall response rate of 22.7% (95% CI: 8%–42%). The main toxicity was hematological: neutropenia grade 3–4 in 28% of the cycles and thrombocytopenia grade 3–4 in 16%. The most significant non-hematological toxicity was asthenia grade 2–3 in 24% of the cycles. Conclusions: This cisplatin plus gemcitabine combination schedule has a favourable toxicity profile with a discrete activity in patients with locally recurrent or metastatic squamous-cell carcinoma of the head and neck.Type of Medium: Electronic ResourceURL: -
4Articles: DFG German National LicensesCastellano, D. ; Lianes, P. ; Paz-Ares, L. ; Hidalgo, M. ; Guerra, J. A. ; Gómez-Martín, C. ; Gómez, H. ; Calzas, J. ; Cortés-Funes, H.
Springer
Published 1998Staff ViewISSN: 1569-8041Keywords: chemotherapy ; gemcitabine ; new drugs ; non-small-cell lung cancerSource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Abstract Background: The aim of this study was to determine the clinical activity and toxicity of a novel chemotherapy combination regimen of gemcitabine plus cisplatin, administered every three weeks, in patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods: Twenty-six previously untreated stages III (14) and IV (12) patients were included. Gemcitabine was administered on days 1 and 8 at a dose of 1250 mg/m2 and cisplatin was administered at a dose of 100 mg/m2 on day 1, every 21 days. Results: Twenty-five patients were evaluable for response. One patient achieved a complete response, and 16 patients partial responses. The overall response rate was 65.3% (95% CI: 45%–82%). The main toxicity was hematological: neutropenia NCIC-CTC grade 3–4 in 54% of the patients, and thrombocytopenia grade 3–4 in 23%. The non-hematological toxicity was mild and tolerable. Only 13% of gemcitabine injections were dose-reduced or omitted due to toxicity. The actual dose-intensity of gemcitabine was 715 mg/m2/week, and 31 mg/m2/week for cisplatin. These figures represent the 86% and 93% of the theoretical dose intensity of both drugs, respectively. With a median follow-up of 10 months (range 7–13), 17 patients are still alive and nine have died. The median overall survival is 12 months. Conclusion: This novel combination of gemcitabine and cisplatin administered every three weeks is well tolerated and induces a remarkably high response rate. The regimen proves more interesting than the four-week schedules, particularly regarding patients who are candidates for local therapy.Type of Medium: Electronic ResourceURL: